Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug
–News Direct– Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Cot CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behet's disease, a rare and debilitating condition. Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases. Cot, with an extensive background in orphan drug approvals from
Read more